Antimicrobial resistance is getting worse. Set to impact healthcare, agriculture and insurance, it’s a phenomenon worth paying attention to. On this episode, we take a look at whether there’s an investment case for fighting back against the superbugs.
Host: Bentley Kaplan, MSCI ESG Research
Guest: Namita Nair, MSCI ESG Research
